Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

Overview
Date Founded

2006

Headquarters

34 Crosby Drive,Suite 105,Bedford, MA 01730

Type of Company

Public

Employees (Worldwide)

167

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology
Medical Products & Equipment

Company Description

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Contact Data
Trying to get in touch with decision makers at Ocular Therapeutix, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer & Principal Accounting Officer

Chief Operations Officer

General Counsel & Chief Intellectual Property Counsel

Chief Technology Officer

Chief Medical Officer

Senior Vice President, Head-Business & Corporate Development

Head of Business & Corporate Development

Director, Human Resources

Senior Vice President-Commercial

Board of Directors

Managing Director at Versant Venture Management LLC

Medical Director at Midwest Surgical Services, Inc.

Co-Director-Vitreoretinal Fellowship at Tufts University - School of Medicine

Former President & Chief Executive Officer at Alba Therapeutics Corp.

Founder at ImmusanT, Inc.

Director, President & Chief Executive Officer at Ocular Therapeutix, Inc.

Former Senior Vice President, Head-Research & Development at Celltrion, Inc.

Paths to Ocular Therapeutix, Inc.
Potential Connections via
Relationship Science
You
Ocular Therapeutix, Inc.
Owners & Shareholders
Details Hidden

Opaleye Management's strategy for managing their fund is to actively invest, both long and short, in equity securities of biotechnology, specialty pharmaceutical and med-device companies. Typically, these are companies that are developing therapies and treatments intended for humans. The fund focuses its long investments in equity securities of companies that may not be profitable yet but whose share price may grow significantly in the near term or over a 1-2 year or longer period based on their therapeutic development and financial objectives. The fund also seeks to actively invest in stock and derivative transactions to profit from \"binary\" events, such as clinical data milestones or a US Food and Drug Administration (FDA) regulatory decision. Conversely, the fund seeks opportunities to short securities that have extended valuations relative to the marketplace. The fund generally invests in equity securities of US and foreign small and mid-cap companies.

Details Hidden

Summer Road specializes in global arbitrage investment strategies.

Details Hidden

Deltec Asset Management specializes in implementing actively managed long-only investment strategies designed to generate positive absolute returns. The firm's strategies are based on the fundamental research of individual securities. Emphasis is placed on the securities of issuers that operate in out-of-favor sectors and/or securities that are poorly understood or underfollowed. Implementation of Deltec's recommendations typically does not involve frequent trading or the use of margin debt, short-sales, or derivatives. Investments include domestic and emerging market equity, debt and equivalent securities. Certain accounts also invest in non-traditional equity and debt securities, including but not limited to, contingent value rights/obligations, interests in liquidating trusts, equity equivalents with due bills entitling the holder to future distributions, defaulted corporate and sovereign debt, interests in fully funded syndicated bank loans, and trade claims.

Recent Transactions
Details Hidden

Ocular Therapeutix, Inc. raised money in a private placement transaction

Details Hidden

Ocular Therapeutix, Inc. issued USD Common Stock

Details Hidden

Ocular Therapeutix, Inc. issued Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Auditor

Advised onOcular Therapeutix, Inc. issued Common Stock

Escrow Agent

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Escrow Agent

Advised onOcular Therapeutix, Inc. issued Common Stock

Co-Chair, Capital Markets Group

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Associate

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Counsel

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Advisors & Consultants
Consultant

Chairman of the Board, Chief Executive Officer, Founder at Instylla, Inc.

Senior Advisor

Consulting Vice President-Regulatory Affairs at Hotspur Technologies, Inc.

Advisor

Managing Director at Westwicke Partners LLC

Key Stats and Financials As of 2018
Market Capitalization
$212M
Total Enterprise Value
$122M
Earnings Per Share
$-1.57
Revenue
$1.99M
Net Profit
$-60M
EBITDA
$-56.8M
EBITDAMargin
-2,855.88%
Total Debt
$24.8M
Total Equity
$35.9M
Enterprise Value Sales
61.52x
TEVNet Income
-2.04x
Debt TEV
0.2x
Three Year Compounded Annual Growth Rate Of Revenue
4.38%
Non-Profit Donations & Grants
$5,000 - $10K
2016
$5,000 - $10K
2015
$5,000 - $10K
2014
Investors
Details Hidden

SV-LSA's core business is to manage or advise partnership funds which provide corporate investors with exposure to the life sciences sector. The firm invests in businesses at all stages of development and across the human life sciences sector, including biotechnology and pharmaceuticals, medical devices and instruments as well as healthcare information technology and services.They primarily focus on North America and Europe, but do not exclude investments in other regions. The firm's policy is to take leading positions in businesses in order to fully support them in their objectives. They focus on companies with a high quality management team and a high potential business model likely to increase in value, and which develop a key technology. They generally invest between USD 1 and 20 million per deal.

Details Hidden

Founded in 1993, SV Health Investors LLC is a venture capital firm headquartered in Boston. The firm is a subsidiary of SV Life Sciences Advisers LLP, a venture capital investment firm based in London. SV Health Investors was formerly known as Schroder Ventures Life Sciences. They advise and manage several venture capital funds for corporate clients and private individuals.

Details Hidden

Chairman & Chief Executive Officer at Imperative Care, Inc.

Suppliers
Incept LLC Other Business & Consulting Services | San Mateo, CA

Incept LLC operates as a biotechnical research company. It focuses in the life-sciences space, and occasional involvement in select information technology opportunities. The company was founded in 1998 by Farhad Khosravi and Amarpreet S. Sawhney and is headquartered in San Mateo, CA.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Becton, Dickinson & Co. Medical Products & Equipment - Franklin Lakes, New Jersey

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. BD is headquartered in the United States and has offices in more than 50 countries worldwide.

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ocular Therapeutix, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ocular Therapeutix, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Ocular Therapeutix, Inc..